AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9145970 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial prophylaxis versus no prophylaxis
Number of subjects: 1482
Study 8159920 — intervention group
Group type: EXPERIMENTAL
Intervention: Castration (orchidectomy)
Number of subjects: 0
Study 8159920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (bisphosphonate)
Number of subjects: 0
Study 3096460 — intervention group
Group type: EXPERIMENTAL
Intervention: Night and day nursery (light and noise reduced between 7 pm and 7 am)
Number of subjects: 41
Study 3096460 — intervention group
Group type: COMPARATOR
Intervention: Control nursery (light and noise not reduced)
Number of subjects: 41
Study 3164333 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration surgical treatment with teflon membrane and chlorhexidine gluconate rinses
Number of subjects: 21
Study 3164333 — intervention group
Group type: COMPARATOR
Intervention: Control treatment procedure (not specified in detail)
Number of subjects: 21
Study 31587431 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement
Number of subjects: 22
Study 31587431 — intervention group
Group type: COMPARATOR
Intervention: Sharp debridement
Number of subjects: 22
Study 30402951 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (BBR)
Number of subjects: 0
Study 30402951 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BBR and rosuvastatin
Number of subjects: 0
Study 28447186 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Volume (HV; 8 sets of 10 repetitions)
Number of subjects: 12
Study 28447186 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity (HI; 8 sets of 3 repetitions)
Number of subjects: 12
Study 25847579 — intervention group
Group type: COMPARATOR
Intervention: Streamlined trial using mobile devices and internet for consent and data entry; participants receive an iPad and EasyOne spirometer for online visits and symptom reporting during an 8-week run-in and a 12-week study period.
Number of subjects: 0
Study 25847579 — intervention group
Group type: COMPARATOR
Intervention: Open-label Advair 250/50 twice daily for 8 weeks followed by randomization to Advair 250/50, Flovent 250, or Advair 100/50, given 1 inhalation twice daily.
Number of subjects: 0
Study 23245760 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 (mu-opioid receptor antagonist)
Number of subjects: 42
Study 23245760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 21194823 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive program of secondary prevention of cardiovascular disease
Number of subjects: 1224
Study 21194823 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1224
Study 18388845 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare-based algorithm for measuring chemotherapy-related toxicities
Number of subjects: 175
Study 18388845 — intervention group
Group type: COMPARATOR
Intervention: CALGB data
Number of subjects: 175
Study 15994064 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg MPH
Number of subjects: 15
Study 15994064 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg MPH
Number of subjects: 15
Study 15994064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 14578916 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment strategy (IND)
Number of subjects: 443
Study 14578916 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise treatment strategy (STEP)
Number of subjects: 443
Study 10953061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear critical velocity model
Number of subjects: 16
Study 10953061 — intervention group
Group type: COMPARATOR
Intervention: Linear critical velocity models
Number of subjects: 16
Study 10953061 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical velocity (CV)
Number of subjects: 16
Study 10953061 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen consumption (VO(2)max)
Number of subjects: 16
Study 9579942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone (doses ranging from 50 to 1,500 mg)
Number of subjects: 96
Study 8265871 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antimicrobial agents
Number of subjects: 0
Study 8265871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines and other biological agents
Number of subjects: 0
Study 8265871 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral stem cell reconstitution
Number of subjects: 0
Study 8265871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene insertion into hematopoietic stem cells
Number of subjects: 0
Study 8265871 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational use of antibiotics
Number of subjects: 0
Study 3533124 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 6
Study 3533124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31597554 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple knee sleeve
Number of subjects: 17
Study 31597554 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple sleeve with patella cutout
Number of subjects: 17
Study 31597554 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 17
Study 28102582 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Cognitive Therapy (PCT) with ADM tapering
Number of subjects: 289
Study 28102582 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Cognitive Therapy (PCT) with maintenance ADM
Number of subjects: 289
Study 28102582 — intervention group
Group type: COMPARATOR
Intervention: Maintenance ADM alone
Number of subjects: 289
Study 26298304 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue PCI with manual thrombus aspiration (TA)
Number of subjects: 70
Study 26298304 — intervention group
Group type: COMPARATOR
Intervention: Rescue PCI without manual thrombus aspiration (NTA)
Number of subjects: 70
Study 23255379 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive behaviour therapy (CBT) anger management intervention facilitated by lay therapists.
Number of subjects: 0
Study 23255379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay therapist role in facilitating CBT groups.
Number of subjects: 0
Study 22024003 — intervention group
Group type: EXPERIMENTAL
Intervention: Family cognitive behavioral therapy (FCBT)
Number of subjects: 71
Study 22024003 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation plus relaxation training (PRT)
Number of subjects: 71
Study 19478423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 0
Study 16792052 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing chewing gum (5 mg of chlorhexidine diacetate)
Number of subjects: 0
Study 14660273 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulse Nd:YAG laser (1064nm)
Number of subjects: 11
Study 14660273 — intervention group
Group type: COMPARATOR
Intervention: Intense pulse light (IPL) system
Number of subjects: 11
Study 10886466 — intervention group
Group type: EXPERIMENTAL
Intervention: Valette
Number of subjects: 63
Study 10886466 — intervention group
Group type: EXPERIMENTAL
Intervention: Neorlest
Number of subjects: 63
Study 9310931 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units (MU) of human lymphoblastoid interferon‐alpha‐n1 (Wellferon) three times per week for either 6 or 12 months
Number of subjects: 38
Study 9310931 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 million units (MU) of human lymphoblastoid interferon‐alpha‐n1 (Wellferon) three times per week for either 6 or 12 months
Number of subjects: 38
Study 8152983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Silver (silver cermet-ionomer cement)
Number of subjects: 53
Study 8152983 — intervention group
Group type: COMPARATOR
Intervention: Delton (conventional, autopolymerizing BIS-GMA resin sealant)
Number of subjects: 53
Study 2423783 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (average dose of 50 mg every 12 h in 11 patients)
Number of subjects: 21
Study 2423783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 21
Study 30989176 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood DNA methylation profile
Number of subjects: 1552
Study 30989176 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation analysis
Number of subjects: 1552
Study 30989176 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic association analysis
Number of subjects: 1552
Study 30989176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 1552
Study 29510953 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of tourniquet during the entire procedure (Group A)
Number of subjects: 54
Study 29510953 — intervention group
Group type: COMPARATOR
Intervention: Use of tourniquet only during cementation (Group B)
Number of subjects: 54
Study 28811120 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance pay based on nutritional status of children
Number of subjects: 4000
Study 28811120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed bonuses
Number of subjects: 4000
Study 28811120 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard salaries
Number of subjects: 4000
Study 25681488 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated feedback system
Number of subjects: 24
Study 25681488 — intervention group
Group type: COMPARATOR
Intervention: Nonfeedback group
Number of subjects: 24
Study 24083021 — intervention group
Group type: EXPERIMENTAL
Intervention: TOGETHER group (active weight loss program)
Number of subjects: 132
Study 24083021 — intervention group
Group type: COMPARATOR
Intervention: ALONE group (only primary participant attended treatment)
Number of subjects: 132
Study 24083021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary changes (calorie and fat intake)
Number of subjects: 132
Study 24083021 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity changes
Number of subjects: 132
Study 21931073 — intervention group
Group type: EXPERIMENTAL
Intervention: manidipine/delapril combination (10/30 mg/d)
Number of subjects: 380
Study 21931073 — intervention group
Group type: EXPERIMENTAL
Intervention: delapril (30 mg/d)
Number of subjects: 380
Study 21931073 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 380
Study 21931073 — intervention group
Group type: EXPERIMENTAL
Intervention: manidipine/delapril combination
Number of subjects: 380
Study 18245680 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 507
Study 18245680 — intervention group
Group type: COMPARATOR
Intervention: Resin-based composite
Number of subjects: 507
Study 16339055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary folate intake
Number of subjects: 37916
Study 16339055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin B(6) intake
Number of subjects: 37916
Study 16339055 — intervention group
Group type: COMPARATOR
Intervention: Total folate intake
Number of subjects: 37916
Study 16339055 — intervention group
Group type: COMPARATOR
Intervention: Total vitamin B(6) intake
Number of subjects: 37916
Study 16339055 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin supplements
Number of subjects: 37916
Study 12588384 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood therapy (ABT)
Number of subjects: 31
Study 12588384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10917114 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol 1 mg daily
Number of subjects: 13
Study 10917114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8768844 — intervention group
Group type: EXPERIMENTAL
Intervention: L-692,429 (0.05 mg/kg · h) for 24 h (low dose)
Number of subjects: 6
Study 8768844 — intervention group
Group type: EXPERIMENTAL
Intervention: L-692,429 (0.1 mg/kg · h) for 12 h, then saline for 12 h (high dose)
Number of subjects: 6
Study 8768844 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 μg/kg, iv) given 30 min before the end of each 24-h treatment
Number of subjects: 6
Study 8768844 — intervention group
Group type: COMPARATOR
Intervention: Saline for 24 h (control)
Number of subjects: 6
Study 2070134 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida protein antigen (CP)
Number of subjects: 133
Study 2070134 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida mannan mitogen (CM)
Number of subjects: 133
Study 2070134 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus protein A (SPA)
Number of subjects: 133
Study 2070134 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell-depleted marrows
Number of subjects: 133
Study 2070134 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades II-IV acute GVHD
Number of subjects: 133
Study 2070134 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed invasive Candida infection
Number of subjects: 133
Study 6311788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 111
Study 6311788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefsulodin
Number of subjects: 111
Study 6311788 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 111
Study 6311788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 111
Study 6311788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 111
Study 6311788 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef (moxalactam)
Number of subjects: 111
Study 6311788 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study 31260642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed informational packet followed by a tailored telephone‐delivered brief motivational interview
Number of subjects: 204
Study 31260642 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 204
Study 29221471 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home balance and proprioceptive training
Number of subjects: 75
Study 29221471 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital supervised balance and proprioceptive training
Number of subjects: 75
Study 29221471 — intervention group
Group type: COMPARATOR
Intervention: Non-active control group
Number of subjects: 75
Study 25928879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythritol tetranitrate (PETN) 80 mg/kg twice daily
Number of subjects: 0
Study 25928879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23523456 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800
Study 23523456 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1800
Study 21740262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track postoperative care
Number of subjects: 50
Study 21740262 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative care
Number of subjects: 50
Study 19958867 — intervention group
Group type: EXPERIMENTAL
Intervention: Elinogrel (10, 20, 40, and 60 mg) administered as a single intravenous bolus before primary PCI
Number of subjects: 70
Study 19958867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19958867 — intervention group
Group type: EXPERIMENTAL
Intervention: Elinogrel (all doses)
Number of subjects: 70
Study 17108847 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch releasing 300 microg/24 hours
Number of subjects: 99
Study 17108847 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 99
Study 14742401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemispheric synchronization (Hemi-Sync) musical recording
Number of subjects: 2
Study 14742401 — intervention group
Group type: COMPARATOR
Intervention: Blank tape (control group)
Number of subjects: 2
Study 11300389 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 10 microg x ml(‐1)
Number of subjects: 40
Study 11300389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl combined with ropivacaine 1 mg x ml(‐1)
Number of subjects: 40
Study 9623379 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic hernia repair
Number of subjects: 20
Study 9623379 — intervention group
Group type: EXPERIMENTAL
Intervention: Open hernia repair
Number of subjects: 20
Study 8688400 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone
Number of subjects: 70
Study 8688400 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 70
Study 8688400 — intervention group
Group type: COMPARATOR
Intervention: Both groups (600 mg and 200 mg mifepristone)
Number of subjects: 70
Study 2176947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 10 micrograms min‐1 kg‐1
Number of subjects: 5
Study 2176947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 5 micrograms min‐1 kg‐1
Number of subjects: 5
Study 2176947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 2 micrograms min‐1 kg‐1
Number of subjects: 5
Study 2176947 — intervention group
Group type: COMPARATOR
Intervention: Control (5% D‐glucose infusion)
Number of subjects: 5
Study 7000063 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and Cefazolin
Number of subjects: 271
Study 7000063 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole and Placebo
Number of subjects: 271
Study 7000063 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin and Placebo
Number of subjects: 271
Study 7000063 — intervention group
Group type: COMPARATOR
Intervention: Double Placebo
Number of subjects: 271
Study 31091980 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (exercise + nutrition education)
Number of subjects: 229
Study 31091980 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 229
Study 31091980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 229
Study 31091980 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 229
Study 27032628 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (30 mg/day)
Number of subjects: 0
Study 27032628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25203371 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 123
Study 25203371 — intervention group
Group type: COMPARATOR
Intervention: No stoma
Number of subjects: 123
Study 21865723 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-burst rTMS
Number of subjects: 22
Study 21519764 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced energy formula diet (200 Kcal every 6 hours for 12 days)
Number of subjects: 120
Study 21519764 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie regular diet (no carbs or fat)
Number of subjects: 120
Study 17945035 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m² on day 1 plus capecitabine 2000 mg/m² daily on days 1-15 (series I)
Number of subjects: 42
Study 17945035 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m² on day 1 plus capecitabine 2000 mg/m² daily on days 1-15 (series II)
Number of subjects: 42
Study 16267371 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute back massage, three times a week for 10 sessions
Number of subjects: 14
Study 16267371 — intervention group
Group type: COMPARATOR
Intervention: Control group relaxed in the same environment for 10 min, three times a week for 10 sessions
Number of subjects: 14
Study 12081122 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (leaflet with risk factors and access to geriatric clinic)
Number of subjects: 1043
Study 12081122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1043
Study 12081122 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 1043
Study 9407262 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEAL model intervention
Number of subjects: 16
Study 8220940 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily for 2 weeks
Number of subjects: 20
Study 8220940 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3612776 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevention program emphasizing refusal skills training
Number of subjects: 1730
Study 3612776 — intervention group
Group type: COMPARATOR
Intervention: No-treatment condition (Control)
Number of subjects: 1730
Study 29288788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrostomy tract infiltration (NTI) with 20 mL of 0.25% ropivacaine and epinephrine (n=32)
Number of subjects: 96
Study 29288788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block with 15 mL of 0.5% ropivacaine and epinephrine (n=32)
Number of subjects: 96
Study 29288788 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=32)
Number of subjects: 96
Study 29288788 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 96
Study 26079158 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Relief (iCBT)
Number of subjects: 138
Study 26079158 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Relief (iCBT)
Number of subjects: 138
Study 26079158 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 138
Study 24767232 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP therapy for 18 months
Number of subjects: 51
Study 22624286 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance before the earthquake
Number of subjects: 16
Study 22624286 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance after the earthquake
Number of subjects: 16
Study 20070284 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (90 microg/week)
Number of subjects: 1049
Study 20070284 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 1049
Study 20070284 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical progression of chronic hepatitis C
Number of subjects: 1049
Study 18616432 — intervention group
Group type: COMPARATOR
Intervention: Morphine (only)
Number of subjects: 32
Study 18616432 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and hydromorphone
Number of subjects: 32
Study 15780537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17beta‐estradiol treatment (300 microg once daily)
Number of subjects: 26